Limited time offer! 10% off your first blood test order!
Hepatitis B and C can silently damage the liver for years before symptoms emerge. A simple fingerstick can tell you where you stand.
or 4 interest-free payments of £12.25 with Klarna
Targeted viral hepatitis screen covering hepatitis B (surface antigen and core antibody) and hepatitis C antibody. Home fingerstick kit available.
Hepatitis B and C are blood-borne viral infections that can be transmitted through sexual contact, sharing needles, or from mother to child. Both can cause chronic liver infection that persists for decades without symptoms, progressively damaging liver tissue and increasing the risk of cirrhosis and liver cancer. The WHO estimates that over 290 million people are living with chronic hepatitis B globally and 58 million with hepatitis C, the majority undiagnosed. In the UK, both infections disproportionately affect certain communities — men who have sex with men, people who inject drugs, those born in high-prevalence countries, and healthcare workers with occupational exposure. This focused screen provides testing for both viruses in one home collection kit, with GMC-registered physician review and clear guidance on next steps if either test is reactive.
Understand what each marker measures, why it matters, and what the science says — not just a list of numbers.
This panel is designed for adults who want a comprehensive, evidence-based picture of their metabolic health — not a GP referral panel.
Anyone who has not been tested for hepatitis B or C and is sexually active
MSM individuals (higher prevalence of hepatitis B)
People who have used injecting drugs at any point in the past
Individuals born in countries with high hepatitis B or C prevalence
Healthcare workers assessing their occupational exposure status
Hepatitis B surface antigen (HBsAg) has a window period of approximately 6 to 8 weeks post-exposure, during which acute infection may not yet be detectable. Hepatitis C antibody testing has a window period of 8 to 12 weeks; a reactive antibody result requires confirmatory hepatitis C RNA testing (PCR) to determine whether active infection is present or whether the antibody reflects a past spontaneously resolved infection (which occurs in approximately 20 to 25 percent of acute hepatitis C cases). Hepatitis B vaccination produces surface antibody (anti-HBs) but not core antibody; the vaccine immunity status cannot be confirmed from this panel alone without additional anti-HBs testing. This panel does not include liver function tests or assessment of hepatic fibrosis.
From order to physician-reviewed report in as little as three working days.
Discreet home fingerstick kit delivered within 2 working days.
Simple fingerstick onto dried blood spot card. Full instructions included.
Pre-paid Royal Mail envelope included.
Secure online report with physician commentary in 3 to 5 working days.
Three options designed to fit your schedule, location, and preference — all producing a laboratory-standard sample.
Adults 18+ in mainland UK. Not suitable if you have had a transfusion in the last 3 months.
Order anytime; kit dispatched within 24 hours Mon–Fri.
Allow 24–48 hours for sample transit on top of lab processing time.
Adults 18+ within 20 miles of a serviced city centre.
Mon–Sun, 06:00–20:00. Next-day booking typical.
Sample reaches the lab within 24 hours of collection.
Adults 16+ with photo ID. Paediatric draws by appointment at selected sites.
Mon–Fri, with Saturday hours at most metropolitan locations.
Samples processed same-day at the receiving clinic.
Every test is processed in a UKAS ISO 15189-accredited laboratory, overseen by GMC-registered physicians, and governed by UK GDPR. No overseas processing, no offshore data.
Follow these guidelines to ensure accurate, reproducible results. Most markers are sensitive to recent food, exercise, and sleep.
Can't find your answer? Our clinical support team is available Monday to Friday, 9am–5pm.
Contact supportHepatitis B cannot currently be cured in the sense of complete viral eradication, but antiviral medications (tenofovir, entecavir) suppress viral replication to undetectable levels in most patients, preventing liver damage and reducing the risk of cirrhosis and hepatocellular carcinoma. Adults who acquire hepatitis B are less likely to develop chronic infection than those infected as children; approximately 95 percent of healthy adults clear acute hepatitis B spontaneously. Chronic hepatitis B requires specialist hepatology care and lifelong monitoring. Effective vaccination is available and provides greater than 95 percent protection against new infection.
Yes. Modern direct-acting antiviral (DAA) treatments for hepatitis C achieve cure rates (sustained virological response) of greater than 95 percent across all genotypes, with a typical treatment course of 8 to 12 weeks of oral medication. Treatment is available through the NHS for all patients with chronic hepatitis C, regardless of stage of liver disease. Detection is the critical first step; once diagnosed, successful treatment prevents cirrhosis, liver cancer, and further transmission. If you have ever injected drugs, received a blood transfusion before 1992, or have other risk factors, testing is strongly recommended.
A reactive hepatitis C antibody indicates that your immune system has produced antibodies in response to hepatitis C virus exposure at some point. It does not by itself confirm active infection. Approximately 20 to 25 percent of people who are infected with hepatitis C clear the virus spontaneously during the acute phase without developing chronic infection. To determine whether hepatitis C is still active, a hepatitis C RNA (PCR) test is required. Your physician commentary will recommend this follow-up test if your antibody is reactive. A positive RNA result confirms active chronic infection and triggers referral for treatment.
The hepatitis B vaccine produces protective surface antibodies (anti-HBs) in over 95 percent of healthy adults who complete the full course (typically three doses). However, a proportion of individuals are non-responders (poor or absent antibody production), and vaccine-induced immunity can wane over time. This panel tests for core antibody and surface antigen but not surface antibody; to confirm your vaccine immunity level, an anti-HBs titre test is required. If you work in healthcare and your immunity status is uncertain, your occupational health department should arrange titre testing.
No. Both infections are frequently completely asymptomatic in the chronic phase. Acute hepatitis B may cause jaundice, fatigue, and flu-like illness, but many people pass through the acute phase unaware. Chronic hepatitis B and C typically produce no symptoms for years or decades while silently causing fibrosis and cirrhosis. By the time symptoms emerge — fatigue, right upper quadrant discomfort, or the signs of advanced liver disease — significant irreversible damage may have occurred. This is precisely why asymptomatic screening is so important for individuals with risk factors.
